Story perspectives

Dividend Kings: AbbVie, J&J, and Enbridge Lead with Strong Yields

9/7/2025

Summary

Story summary

AbbVie has raised its dividend by 310% since 2013, currently yielding 3.1%.
Eli Lilly focuses on expanding its drug portfolio, targeting obesity and diabetes treatments.
Johnson & Johnson has increased dividends for 63 consecutive years, despite ongoing legal challenges.
Enbridge provides a 5.65% yield, supported by a stable model for transporting crude oil and natural gas.
Realty Income, a REIT, offers a 5.57% yield with a diversified focus on low-risk retail properties.

History

Historical Context

In 2013, AbbVie was spun off from Abbott Laboratories, reshaping the pharmaceutical sector. Since then, AbbVie has increased its dividend by 310%, while Johnson & Johnson has achieved 63 consecutive years of dividend growth. This trend highlights a broader corporate commitment to shareholder value, as companies like Enbridge and Realty Income navigate economic fluctuations and legal challenges.

1 of 2

Story summary

AbbVie has raised its dividend by 310% since 2013, currently yielding 3.1%.
Eli Lilly focuses on expanding its drug portfolio, targeting obesity and diabetes treatments.
Johnson & Johnson has increased dividends for 63 consecutive years, despite ongoing legal challenges.
Enbridge provides a 5.65% yield, supported by a stable model for transporting crude oil and natural gas.
Realty Income, a REIT, offers a 5.57% yield with a diversified focus on low-risk retail properties.

1 / 2